Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Secreted frizzled-related protein promotors are hypermethylated in cutaneous squamous carcinoma compared with normal epidermis

Authors: Junqin Liang, Xiaojing Kang, Yilinuer Halifu, Xuewen Zeng, Tianbo Jin, Mingxia Zhang, Dong Luo, Yuan Ding, Yunmin Zhou, Buwajier Yakeya, Dilinuer Abudu, Xiongming Pu

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

The Wnt signaling pathway is abnormally activated in many human cancers. Secreted frizzled-related proteins (SFRPs) function as negative regulators of Wnt signaling and play an important role in carcinogenesis. SFRP promoter hypermethylation has often been identified in human cancers; however, the precise role of SFRPs in cutaneous squamous cell carcinoma (SCC) is unclear.

Methods

The methylation status of the SFRP family was analyzed in an age-and sex-matched case-control study, including 40 cutaneous SCC cases and 40 normal controls, using the MassARRAY EpiTYPER system.

Results

The methylation rate of SFRP1, SFRP2, SFRP4, and SFRP5 promoters was significantly higher in cutaneous SCC tissues than in adjacent tissue and normal skin samples.

Discussion

Our manuscript mainly discussed the average methylation rate of SFRPs (SFRP1, SFRP2, SFRP4, and SFRP5) promoters are significantly high in tumor tissue samples and the average CpG island methylation rate among different pathological levels of cutaneous SCC between these genes are different.

Conclusions

Our findings suggest that promoter hypermethylation of SFRPs is associated with the development of carcinoma, and could be a useful tumor marker for cutaneous SCC and other types of cancers.
Literature
1.
Hameetman L, Commandeur S, Bavinck JNB, Wisgerhof HC, de Gruijl FR, Willemze R, et al. Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients. BMC Cancer. 2013;13(1):58.CrossRefPubMedPubMedCentral
2.
3.
4.
Thomas RF, Scotto J. Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure. Cancer Invest. 1983;1(2):119–26.CrossRef
5.
Proby C, Harwood C, Neale R, Green A, Euvrard S, Naldi L, et al. A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant. 2011;11(7):1498–508.CrossRefPubMed
6.
Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11(24):3286–305.CrossRefPubMed
7.
Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837–51.PubMed
8.
Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC−/− colon carcinoma. Science. 1997;275(5307):1784–7.CrossRefPubMed
9.
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.CrossRefPubMed
10.
Jones SE, Jomary C. Secreted Frizzled‐related proteins: searching for relationships and patterns. Bioessays. 2002;24(9):811–20.CrossRefPubMed
11.
Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 2004;64(3):883–8.CrossRefPubMed
12.
Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene. 2004;23(39):6672–6.CrossRefPubMed
13.
Suzuki H, Watkins DN, Jair K-W, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36(4):417–22.CrossRefPubMed
14.
Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res. 2006;12(7):2109–16.CrossRefPubMed
15.
Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31(2):141–9.CrossRefPubMed
16.
Zhou Z, Wang J, Han X, Zhou J, Linder S. Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors. Int J Cancer. 1998;78(1):95–9.CrossRefPubMed
17.
Wong SCC, Lo SFE, Cheung MT, Ng KOE, Tse CW, Lai BSP, et al. Quantification of plasma β-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res. 2004;10(5):1613–7.CrossRefPubMed
18.
Pourreyron C, Reilly L, Proby C, Panteleyev A, Fleming C, McLean K, et al. Wnt5a is strongly expressed at the leading edge in non-melanoma skin cancer, forming active gradients, while canonical Wnt signalling is repressed. PLoS One. 2012;7(2):e31827.CrossRefPubMedPubMedCentral
19.
Cheng S, Luk N, Chong L. Special features of non-melanoma skin cancer in Hong Kong Chinese patients: 10-year retrospective study. Hong Kong Med J. 2001;7(1):22–8.PubMed
20.
Novakovic B, Wong NC, Sibson M, Ng H-K, Morley R, Manuelpillai U, et al. DNA methylation-mediated down-regulation of DNA methyltransferase-1 (DNMT1) is coincident with, but not essential for, global hypomethylation in human placenta. Journal of Biological Chemistry. 2010;285(13):9583–93.CrossRefPubMedPubMedCentral
21.
Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005;102(44):15785–90.CrossRefPubMedPubMedCentral
22.
Kampfrath T, Levinson SS. Brief critical review: statistical assessment of biomarker performance. Clin Chim Acta. 2013;419:102–7.CrossRefPubMed
23.
Lin Y-W, Chung M-T, Lai H-C, De Yan M, Shih Y-L, Chang C-C, et al. Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol. 2009;135(12):1665–74.CrossRefPubMed
24.
Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2002;196(1):1–7.CrossRefPubMed
25.
26.
Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJG, et al. Secreted frizzled related proteins: Implications in cancers. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2014;1845(1):53–65.CrossRef
27.
Schiefer L, Visweswaran M, Perumal V, Arfuso F, Groth D, Newsholme P, et al. Epigenetic regulation of the secreted frizzled-related protein family in human glioblastoma multiforme. Cancer Gene Ther. 2014;21(7):297–303.CrossRefPubMed
28.
Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61(1):249–55.PubMed
29.
Nikolaidis G, Raji OY, Markopoulou S, Gosney JR, Bryan J, Warburton C, et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res. 2012;72(22):5692–701.CrossRefPubMedPubMedCentral
30.
Baylin SB. Mechanisms underlying epigenetically mediated gene silencing in cancer. In: Seminars in cancer biology: 2002. Elsevier; 2002: 331–337.
31.
Chung M-T, Sytwu H-K, Yan M-D, Shih Y-L, Chang C-C, Yu M-H, et al. Promoter methylation of SFRPs gene family in cervical cancer. Gynecol Oncol. 2009;112(2):301–6.CrossRefPubMed
32.
Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY, et al. Promoter methylation of the secreted frizzled‐related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 2006;107(3):579–90.CrossRefPubMed
33.
Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, et al. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer. 2007;121(5):1028–35.CrossRefPubMed
Metadata
Title
Secreted frizzled-related protein promotors are hypermethylated in cutaneous squamous carcinoma compared with normal epidermis
Authors
Junqin Liang
Xiaojing Kang
Yilinuer Halifu
Xuewen Zeng
Tianbo Jin
Mingxia Zhang
Dong Luo
Yuan Ding
Yunmin Zhou
Buwajier Yakeya
Dilinuer Abudu
Xiongming Pu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1650-x

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

The preoperative SUVmax for 18F-FDG uptake predicts survival in patients with colorectal cancer

Research article

Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma

Research article

Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound

Case report

Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses

Study protocol

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer

Research article

MTA2 enhances colony formation and tumor growth of gastric cancer cells through IL-11
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits